相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs
Astrid A. M. Van der Veldt et al.
CANCER CELL (2012)
Vascular and Metabolic Response to Bevacizumab-Containing Regimens in Two Patients With Colorectal Liver Metastases Measured by Dynamic Contrast-Enhanced MRI and Dynamic 18F-FDG-PET
Dennis Vriens et al.
Clinical Colorectal Cancer (2012)
Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer
Leonard Saltz et al.
CLINICAL COLORECTAL CANCER (2012)
Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model
Cinthia V. Pastuskovas et al.
MOLECULAR CANCER THERAPEUTICS (2012)
EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies
Virginie Poindessous et al.
CLINICAL CANCER RESEARCH (2011)
Cetuximab after bevacizumab in metastatic colorectal cancer: Is it the best sequence?
Emmanuelle Norguet et al.
DIGESTIVE AND LIVER DISEASE (2011)
Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model
Bianca A. W. Hoeben et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
ImmunoSPECT and ImmunoPET of IGF-1R Expression with the Radiolabeled Antibody R1507 in a Triple-Negative Breast Cancer Model
Sandra Heskamp et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
111In-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib
Ingrid M. E. Desar et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Investigation of the efficacy of a bevacizumab-cetuximab-cisplatin regimen in treating head and neck squamous cell carcinoma in mice
Yixiang Wang et al.
TARGETED ONCOLOGY (2010)
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
U-SPECT-II: An Ultra-High-Resolution Device for Molecular Small-Animal Imaging
Frans van der Have et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
FDA Drug Approval Summary: Bevacizumab (Avastin (R)) as Treatment of Recurrent Glioblastoma Multiforme
Martin H. Cohen et al.
ONCOLOGIST (2009)
High resolution dynamic total-body animal imaging with U-SPECT-II
Brendan Vastenhouw et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells
Roberto Bianco et al.
CLINICAL CANCER RESEARCH (2008)
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver
Michael J. Gray et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
VEGF-targeted therapy: mechanisms of anti-tumour activity
Lee M. Ellis et al.
NATURE REVIEWS CANCER (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells
Nikolaos A. Dallas et al.
CANCER AND METASTASIS REVIEWS (2007)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer
Aleksandra Franovic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB
H. L. Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy
JR Tonra et al.
CLINICAL CANCER RESEARCH (2006)
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer
SB Wedam et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells
F Fan et al.
ONCOGENE (2005)
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts
T Inai et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model
YD Jung et al.
EUROPEAN JOURNAL OF CANCER (2002)
Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors
RM Shaheen et al.
BRITISH JOURNAL OF CANCER (2001)
分享论文
